PC3Q14中文资料
PC3H4中文资料
Response time (µs)
1000 500
200 100 50
VCE=2V IC=2mA Ta=25°C
20
tr
tf
10
5
td
2
ts
1
0.5
0.2
0.1
0.01
0.1
1
10
100
Load resistance RL (kΩ)
Fig.14 Collector-emitter Saturation Voltage vs. Forward Current
500 VCE=5V Ta=25°C
400
Current transfer ratio CTR (%)
300
200
100
0
0.1
1
10
100
Forward current IF (mA)
PC3H4/PC3Q64Q
Fig.4 Total Power Dissipation vs. Ambient Temperature
100
0˚C
50
−25˚C
Forward current IF (mA)
20 10 5
2 1
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
Forward voltage VF (V)
Fig.8 Collector Current vs. Collector-emitter Voltage
Fig.2 Diode Power Dissipation vs. Ambient Temperature
100
80 70 60
40
20
0
−30
0
产品标准信息库(板材)
薄板厂以冷轧钢带或热轧酸洗钢带为基板、通过连续热镀锌工艺生产0.25~2.22mm钢板及钢带。 ≤0.22 ≤1.50 薄板厂以冷轧钢带或热轧酸洗钢带为基板、通过连续热镀锌工艺生产0.25~2.23mm钢板及钢带。 ≤0.22 ≤1.50 薄板厂以冷轧钢带或热轧酸洗钢带为基板、通过连续热镀锌工艺生产0.25~2.24mm钢板及钢带。 ≤0.22 ≤1.60
≤0.025
≤0.30
≤0.30
Hale Waihona Puke ≤0.30≤0.030 ≤0.030 ≤0.030 ≤0.030 ≤0.030 ≤0.030 ≤0.030
≤0.025 ≤0.025 ≤0.025 ≤0.025 ≤0.025 ≤0.025 ≤0.025
≤0.30 ≤0.30 ≤0.30 ≤0.30 ≤0.30 ≤0.30 ≤0.30
热轧汽车车轮用钢
Q/BG 560—2014
DP540
热轧汽车结构用钢
Q/BG 562—2014
DP590
热轧汽车结构用钢
Q/BG 562—2014
DP600
热轧汽车结构用钢
Q/BG 562—2014
DP700
热轧汽车结构用钢
Q/BG 562—2014
DP780
热轧汽车结构用钢
Q/BG 562—2014
用于制造汽车轮辐、轮辋及
横 梁、纵梁、护板、保险杠等结构件
工程厚度mm：2.0～12.0
（酸洗2.0～8.0） ≤0.20 ≤0.80 ≤1.80
用于制造汽车轮辐、轮辋及
横 梁、纵梁、护板、保险杠等结构件
工程厚度mm：2.0～12.0
（酸洗2.0～8.0） ≤0.20 ≤1.00 ≤2.00
Q2(R2)-Q14_EWG_Business-Plan
Final Business PlanICH Q14: Analytical Procedure Development and Revision of Q2(R1) AnalyticalValidationdated 14 November 2018Endorsed by the Management Committee on 15 November 20181.The issue and its costs•What problem/issue is the proposal expected to tackle?Since there is no ICH guideline on Analytical Procedure Development, applicants often report analytical validation results alone and rarely present performance evaluation with analytical development outcomes. This makes regulatory communication unproductive when non-conventional (e.g., multivariate models for process control) analytical procedures are employed. Additionally, the lack of guideline impedes opportunities for the applicant to present a scientific basis for flexible regulatory approaches (e.g.,Quality by Design concept) to post-approval Analytical Procedure changes.The current Q2(R1) “Guideline on Validation of Analytical Procedures: Text and Methodology” is not directly applicable to analytical procedures such as Near Infrared (NIR) Spectroscopy. The lack of clear guidelines can lead to submissions with inadequate validation data for these analytical procedures, resulting in recursive information requests and responses, which can delay application approval. The delays are often the case for procedures reliant on multivariate models, a category for which no ICH validation guideline exists. Such methods are commonly used in process control and real time testing of pharmaceutical products. Taking into consideration the differences between multivariate and traditional methods, the current approach outlined in Q2(R1) is not sufficient to establish suitability of multivariate analysis methods using spectroscopic or spectrometric data.•What are the costs (social/health and financial) to our stakeholders associated with the current situation or associated with “non action”?Non-action leads to delayed access to medication and potential increase of costs to patients because of multiple rounds of information requests resulting in delay of approval. The current situation also deprives industry of an opportunity to present the knowledge obtained through applying the enhanced approaches to analytical procedures, and to provide a scientific basis for more robust methods and more flexible regulatory approach. Thus, currently more resources for change management are required and this will remain the case in the absence of Q2(R1) revision. In addition, new continuous manufacturing approaches being applied in the pharmaceutical industry (for both biologics and synthetic-based products) require fast, real time test methods (e.g.,NIR and Raman spectroscopy, and in the future mass spectrometry) to assure that the process is in a state of control all of the time.However, the current version of Q2(R1) does not provide guidance for validation of analytical methods based on multivariate data. Overall, the impetus for industry to develop robust analytical methods for such continuous processes is diminished and delays implementation of efficient processes for new drug manufacturing and quality control testing. The revisions proposed present a more comprehensive guideline to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human UseICH Secretariat, Route Pré-Bois 20, P.O. Box 1894, 1215 Geneva, Switzerlanddevelop and validate analytical procedures and will reduce additional burden associated with repetitive regulatory review of applications for drug approval.2.Planning•What are the main deliverables?The objective of this proposal is to provide an opportunity to present the knowledge obtained through applying enhanced approaches to validation of analytical procedures, to provide the guidance on how to apply and to indicate a policy for more flexible regulatory approaches. The proposed guideline will facilitate selecting or identifying conditions for methods and/or model updates and re-validations that ease assessment of post-approval changes by regulatory agencies and enable more efficient and sound scientific and risk-based change management. Applying the enhanced approach for analytical procedures (i.e., Quality by Design) will contribute to the resource-efficient drug development and streamline post-approval CMC changes.•What resources (financial and human) would be required?Because activities are strongly interrelated, one Expert Working Group will be designated to establish the new Analytical Procedure Development and revise ICH Q2(R1). This dedicated Expert Working Group will potentially determine the feasibility to combine both documents in to one for simplification and clarity. An Expert Working Group composed of experts with knowledge and proficiency in the area of analytical chemistry and pharmaceutical control is needed.•What is the time frame of the project/milestones?By Fall 2018; Final Concept Paper, The first Face to Face EWG meetingSpring 2019; 2nd F2F EWG meetingFall 2019; 3rd F2F EWG meeting(Finish two drafts to be reviewed within Member/Observer parties for both).Spring 2020; 4th F2T EWG meeting(Step 2 for both)Spring 2021; 5th F2F EWG meeting(Step 4 for both)•What special actions to advance the topic through ICH, e.g. stakeholder engagement or training, can be anticipated either in the development of the guideline or for its implementation?Case studies can be collected to help discussion at EWG meeting and to form the basis of training materials of the guidelines when implemented.3.The impacts of the project•What are the likely benefits (social, health and financial) to our key stakeholders of the fulfilment of the objective?The proposal can provide timely access to new drugs for patients by elimination of multiple review cycles. In addition, clear guidance in this area may encourage the use of more advanced analytical procedures and modernization of existing methods, leading to more robust quality oversight by pharmaceutical drug manufacturers. •What are the regulatory implications of the proposed work – is the topic feasible(implementable) from a regulatory standpoint?These guidelines would have no legal issues, be in alignment with ICH Q8-12, and have no impact on the existing regional regulatory procedures.•Will the guideline have implications for the submission of content in the CTD/eCTD? If so, how will the working group address submission of content in the dossier? Will a consult be requested with the ICH M8 working group?Although the new guideline Q14 will be for S4, P4 and P5 of CTD, there will be no necessity to change the CTD/eCTD sections and ICH M8 documents.4.Post-hoc evaluation•How and when will the results of the work be evaluated?The benefits of these guidelines would be evaluated after the implementation.The impact of the new guideline could be evaluated based on the information described in the submitted document by a survey in all agencies.。
pc3k12通用模块说明精简汉化
目录1.PC-3000 综合工具1.1 用途1.2 PC-3000软件部分, 版本10.101.3 PC-3000综合工具套件, 版本10.101.4 质量保证1.5 用户注册1.6 PC-3000注册用户支持1.7 PC-3000综合工具的安装2.用于诊断和维修任何类型的硬盘驱动器的通用测试工具 (PC-3000AT) 2.1 用途2.2 准备工作2.3 PC-3000AT工作时的输出信息2.4 为待测硬盘驱动器输入参数2.5 PC-3000AT的工作模式2.5.1 工作模式选择2.5.2 查看硬盘驱动器的S.M.A.R.T参数2.5.3 驱动器测试2.5.4 控制器测试2.5.5 综合测试2.5.5.1 综合测试的组成2.5.6 缺陷重设2.5.6.1 自动重设2.5.6.2 手动重设2.5.6.3 撤消重设2.5.7 格式化3.PC-3000 SHELL 外壳程序4.PC-DEFECTOSCOPE 缺陷探测器 Ver.2.104.1 用途4.2 准备工作4.3 使用PC-DEFECTOSCOPE工作4.4 进行测试4.5 将PC-DEFECTOSCOPE用于硬盘维修4.6 输出的缺陷列表文件的结构---------------------------------------1.2 PC-3000 软件部分Universal software 通用软件PC-3000 SHELL PC-3000 外壳程序是PC-3000综合工具中用于快捷方便的启动各个工具的图形化界面.PC-3000AT Ver. 4.05 用于诊断和修理任何类型的硬盘驱动器的通用测试工具PC-DEFECTOSCOPE 缺陷探测器 Ver 2.10 用于搜索和隐藏不稳定坏扇区的通用程序 PC-ACIDENT 西部数据(WD)AC系列硬盘驱动器的识别工具---------------------------------------2.当你维修一台硬盘驱动器时. 不要急于马上开始使用专用工具模块. 首先, 任何硬盘驱动器都应该先用包含在本综合工具中的PC-3000AT通用测试工具进行检查. 这样可以有助于缩小故障范围,从而决定下一步的维修操作.在使用PC-30000AT对硬盘驱动器进行测试并做出了关于它的缺陷的初步判断后, 你就可以启动一个专用工具模块进行更高级的诊断或修复硬盘驱动器的固件. 以厂家所用的方法(factory mode 工厂模式)进行,硬盘驱动器修复的方法的详细描述放在专用工具模块的说明部分2.1 作用PC-3000AT 测试软件是PC-3000综合工具中用于IDE(ATA接口)硬盘驱动器维修和恢复的基本程序，被设计用于：1.以较一般的方式诊断缺陷, 修理IDE硬盘驱动器.2.使用ATA标准命令50H(格式化磁道命令 --译者注)进行低级格式化来正确修复硬盘驱动器.3.在支持缺陷重设机制(defect reassign)的硬盘驱动器上(用缺陷重设机制)隐藏坏扇区.4.以用户输入参数,软件输出信息的操控形式进行自动化驱动器测试(指综合测试模式)2.5 PC-3000AT 的工作模式2.5.1 MODE SELECTION 工作模式选择在工作模式选择菜单中可以用上([Up])下([Down])光标键及回车([Enter])键选择工作模式, 用[Cancel]和[Exit]键退出所选择的工作模式.工作模式选择菜单的主菜单:MODE SELECTION (工作模式选择)Drive type selection (硬盘驱动器类型选择)Drive test (驱动器测试)Controller test (控制器测试)Complex test (综合测试)Defects relocation (缺陷重设)Formatting (格式化)Exit (退出)各个按键作用:按PC-3000AT测试工具的键盘(电脑键盘右部的数字小键盘区上预设)上的键可执行下列功能.[Tran.]按键 : 硬盘驱动器扇区逻辑地址转换物理地址正确性测试[Step-]按键 : 磁头后退一个磁道,当前活动柱面号减1[Step+]按键 : 磁头前进一个磁道,当前活动柱面号加1[X->0] 按键 : 硬盘驱动器重新校准, 也就是把磁头移动到零磁道上[A<->B]按键 : 磁头在两个指定磁道之间反复移动[RND]按键 : 磁头在两个指定磁道之间的各磁道随机寻道[Eras]按键 : ERASE(擦除),将硬盘驱动器的所有扇区写零[View]按键 : 在屏幕上查看硬盘驱动器的扇区内容[Wrt]按键 : 选择一个代码, 写入当前磁道的所有扇区[Hd]按键 : 切换(选择)磁头2.5.5 Complex test 综合测试Complex test 综合测试 -由用户输入参数,PC-3000AT输出信息操控形式的工作模式. 综合测试期间按顺序执行下列测试:Controller test 控制器测试IRQ test 硬件中断请求IRQ测试Sector buffer test 扇区缓存测试Recalibration test 磁头重新较准测试Format check 格式化检查Random reading 随机读取Surface scanning 表面扫描屏幕上会显示以下消息:ATTENTION! 注意!Testing will destroy your data 测试会破坏你的数据start cylinder: X 开始柱面: Xend cylinder: XXXX 结束柱面：XXXXdo write test: Yes 进行写入测试：是press [Enter] or [Cancel] 按[Enter]或[Cancel]键Surface scanning 表面扫描-- 这项测试用于逐个扇区的扫描硬盘驱动器扇区数据格式中的扇区数据字段(一般IDE硬盘驱动器的每个扇区上的数据可划分为扇区地址ID字段和扇区数据字段两个部分, 其中扇区数据字段一般为512字节用于存放用户数据, 再加4个字节的用户数据CRC校验码用于保证数据完整性 --译者注). 在测试时, 测试代码6DB6H会写到磁道上的每一个扇区上, 随后再读出来, 比较写入与读出的信息. 如果在综合测试的设置选项中关闭了写入, 则只进行读取而不进行数据比较. 在比较写入与读出的代码时, 如果发现不匹配, 那么就会在测试结果清单中写入错误码FFH. 缺陷扇区的相关数据可用于在表面扫描检查之后进行的缺陷重设过程. 如果在"Surface scaning表面扫描"测试过程中检测到了错误, 那么在查看测试结果清单之后屏幕上会显示如下菜单:SELECT ACTION 选择行动Do not relocate defects 不重设缺陷Relocate detected defects 重设检测到的缺陷2.5.6 Defects relocation 缺陷重设这个模式设计用于在支持缺陷重设机制的硬盘驱动器上重设及隐藏有缺陷存在的坏扇区. 缺陷重设可以在自动化表面扫描模式下进行, 也可在手动输入坏扇区地址参数的模式下进行.当缺陷重设工作模式启动时, 屏幕上会显示如下菜单.Automatic relocation 自动化缺陷重设Manual relocation 手动缺陷重设Undo relocation 撤消重设建议把缺陷重设过程多进行几次, 每次都随后用综合测试检测没有被重设的缺陷扇区.---------------------------------------3. PC-3000 SHELLPC-SHELL(外壳)软件是设计用来更加方便的使用PC-3000综合工具. 当启动PC-3000 SHELL(外壳)时, 会有一个硬盘驱动器制造商及对应的PC-3000专用工具？榈牧斜硐允驹谄聊簧? 这个表的第一行被UNIVERSAL UTILITES(通用工具模块)所占据 , PC-3000AT工具模块和 PC-DEFECTSCOPE工具模块可从此处进---------------------------------------4. PC-DEFECTOSCOPE 缺陷探测器 Ver 2.104.1 用途PC-DEFECTOSCOPE 工具是被设计用来在任何支持缺陷重设机制的硬盘驱动器上检测和重设"unstable sectors(不稳定扇区)的, 测试结果能被输出到一个文件中, 以用于在后面使用特定于此一硬盘驱动器的专用工具模块进行缺陷重设(例如, 富士通专用工具模块或西部数据专用工具模块). 所谓"unstable sectors (不稳定扇区)"是指那些读(写)时间远远大于此硬盘的平均扇区读(写)时间的扇区. 一般来说, "不稳定扇区"出现的那些地方, 缺陷有时会有时不会显示出来, 或者缺陷是由被损坏的伺服码引起的. 此工具启动时你必须选择扇区定址模式：LBA addressing (LBA 逻辑块定址模式)CHS addressing (CHS 柱面,磁头,扇区定址模式)对硬盘驱动器进行测试的模式依赖于上面的选择. 要记住的是, 早期型号容量不超过500-850MB的硬盘驱动器不支持LBA定址模式, 而CHS定址模式只允许你测试容量不超过8.4GB的硬盘驱动器. PC-DEFECTSCOPE输出的数据文件(*.dft)格式也依赖于对 CHS/LBA定址模式的选择. 因此要想在后面使用特定的专用工具模块重设不稳定扇区必须要考虑以上几个因素. 例如, 设计用于老型号WD(西部数据)的专用工具模块只可用CHS定址模式下的*.dft文件工作, 而新型号却只能用LBA定址模式的, 而Fujitsu(富士通)硬盘驱动器两种格式都支持.扇区定址模式选择过后, 屏幕上会显示如下警告信息:Thershold index 极限指数 (2-9) 3Dynamic threshold 动态极限 No 否Starting cylinder 开始柱面 0Ending cylinder 结束柱面 XXXNumber of verification passes 校验遍数 1Turn off che cache 关闭缓存 Yes 是Perform writing 进行写测试 No 否[Ener] -continue [Esc] -cancel [Enter]键- 继续 [Esc]键- 取消thersold index 极限指数是一个范围2到5之间的数值, 它决定了时间限制, 超过这个读写时间值的柱面会被认为有缺陷存在. 在测试开始之前会测量柱面或LBA块的平均访问时间. 获得的时间会被乘以极限指数作为临界值输入完所有需要的参数, 按[Enter] 键启动 "Track time verification test".此测试完后按[Enter]启动 "Sector access time test".测试完成后你可以反复使用 [R], [A], 和 [L] 键或进行危险极限值选择. 重复键有以下功能:[R] - 重复功能, 允许重复进行扇区存取时间测试并将结果加到前面的结果中;[A] - 重复测试并累加结果, 允许重复进行扇区存取时间测试并把结果累加到前面的结果中;[L] 循环重复测试并累加结果数据.如果需要保存结果到文本文件, 按 [F2].如果发现有缺陷, 下面菜单将会出现:SELECT ACTIONDo not relocate defects 不重设缺陷Relocate detected defects (assign) 重设探测到的缺陷(assign)Write defects to a binary file 写缺陷信息到一个二进制文件[ESC] - exit 退出4.5.将PC-Defectoscope 用于硬盘维修PC-Defectoscope 工具可以用来隐藏Fujitsu(富士通)和WD(西部数据)硬盘驱动器的"不稳定扇区" .要对富士通驱动器进行缺陷重设则在完成检测之后需要选择菜单项 "Write defects to a binary file" .所有的缺陷扇区都将写到一个 *.dft 文件中. 接着你必须在Fujitsu(富士通)专用工具模块中选择 "Defects Table, Import Log of the Defects Table" 菜单项并装载缺陷信息到P-List表中. 之后你就可以进行低级格式化处理了.你可以使用同样的方法来处理 WD(西部数据)硬盘驱动器的缺陷,或者也可试着用缺陷重设模式- 在完成缺陷检测之后你可以选择 "Relocate Detected Defects (Assign)" 选项. 将把所有的缺陷扇区加入到WD(西部数据)硬盘驱动器的 G-List 表中. 之后你需要选择菜单项 "Defects Table, Group into Tracks" 在 WD专用工具模块中并把缺陷扇区转为缺陷磁道, 如果缺陷扇区超过5个以上. 那么建议在工具模块中移动 G-List 到 P-List 并根据P-List来进行低级格式化处理.。
NSF14中文
元件認證指南目錄飲用水處理系統和元件認證指南章節-----------------------------------------------------------------------------------頁碼序--------------------------------------------------------------------------------------1-4 概況-----------------------------------------------------------------------------------5常見問題-----------------------------------------------------------------------------6-8 NSF標準規定-----------------------------------------------------------------------9-15 認證-----------------------------------------------------------------------------------15-18 與供應商合作-----------------------------------------------------------------------19詞彙表--------------------------------------------------------------------------------20-24 附錄A--------------------------------------------------------------------------------25附錄B--------------------------------------------------------------------------------26附錄C--------------------------------------------------------------------------------27-28 聯絡資訊-----------------------------------------------------------------------------29序NSF International（簡稱NSF）成立於1944年，為一個致力於公共衛生安全以及環境保護的機構。
JQX-14FC1CZ3中文资料
Features
Heavy load, suitable for heavy power reverse. Small size, suitable for high-density mounting. Up to 5000VAC dielectric strength. Between open contacts of JQX-14FC3 3000VAC dielectric strength. Contact gap of JQX-14FC3 :2y1.5mm=3mm. Suitable for remote control TV set, copy machine, sales machine and air conditioner etc.
Ordering Information
JQX-14FC1
1
C S 10 DC12V 0.8 3.5
2 3 4 5 6 7 4 Contact Current：3A,5A,6A,8A,10A,16A,20A 5 Coil rated Voltage(V)：DC:3,5,6,9,12,15,24 6 Coil power cunsumption：NIL:0.53W ；0.8:0.8W ；1.2:1.2W 7 Pole-distance：3.5:3.5mm；5:5.0mm
-25~75(JQX-14FC3
Qualification inspection:
Perform the qualification test as specified in the table of IEC255-19-1 and minimum sample size 24.
Safety approvals Safety approval Load
14Q 培训教材
控制计划中详细定义了检测工具类型及 CP中已经有详细定义检测工具类型 其用途？
所有的检测工具都仅被允许在标示的监 QMM7会提前发通知，会提醒MOE送检 控有效期内使用
价值流 Q-Basics
原则 6
Q6的主旨是： 1.确认有对机台进行校正，并有 记录
采用对“检测‘者’进行检查” (Check the Checker) 的原则，并能够验证“检测‘者’” 的适用性。
价值流 Q-Basics
原则 5
Q5的主旨是： 1.所有员工知道使用前要看校验 标签
确定量检具并按规定的时间间隔进行监控。
价值流 Q-Basics
原则 5
检测工具校准间隔有被监控？ QMM7会提前发通知，已定义MOE负责 QMM7即仪校室，查核本部门每个仪 人 器是否有专人负责（负责检查校验是 否过期）每个员工要知道检具上要有 标签，并且在使用有效期之内
参与是强制性的，且被记录？
所有差异应使用8D的方法来解决？
价值流 Q-Basics
原则 3
WI ：
PSS：
价值流 Q-Basics
原则 3
8D ：
价值流 Q-Basics
原则 4
Q4的主旨是： 1.WI对设备参数进行定义，此参 数指的是与产品质量相关 2.可视
确保所有给定的过程参数的目标值 / 公 差均得到遵循。
同样规定了生产部门和支持部门在其 TEF定义了TPM的组织架构、保养维护标 准和实施人员 中的角色和职责。
针对机械设备和工装夹具的系统损害 TEF负责维修和更换，需要提高分析能力 和污染都进行了持续地分析，理解根 源并排除。
价值流 Q-Basics
原则 8
应确定所有刀具的使用寿命；必须能够识别其当前 状态。 在移除或拆卸时必须对其进行质量评估。
14Q--培训资料
7
such as copying and passing on to third parties.
CI XI XinYue
CI XI XinYue Electric Appliances Co., reserves all rights even in the event of industrial property rights. We reserve all rights of disposal
3
such as copying and passing on to third parties.
CI XI XinYue
CI XI XinYue Electric Appliances Co., reserves all rights even in the event of industrial property rights. We reserve all rights of disposal
Eg.
1、现场发现不良反馈机制 2、中断作业标准要求
CI XI XinYue
CI XI XinYue Electric Appliances Co., reserves all rights even in the event of industrial property rights. We reserve all rights of disposal
通知IPN工厂
1
CI XI XinYue
CI XI XinYue Electric Appliances Co., reserves all rights even in the event of industrial property rights. We reserve all rights of disposal such as copying and passing on to third parties.